Dedicated to bioresearch for decades, Chemz International PTE. LTD has mastered the integration of production and research in the biological pharmacy sector, significantly enhancing its sustainable core competitiveness. In 2010, the company made substantial investments to establish a state-of-the-art research and production facility for insulin and its analogs in Zhuhai. This facility includes eight new manufacturing shops, with all key equipment sourced from manufacturing leaders such as Germany, France, and Italy, ensuring top-tier production quality. Currently, the facility boasts three insulin-like API lines (rh-insulin, insulin glargine, and insulin aspart) and three preparation lines, including the pioneering USLEN pre-filled pen line—the first such line approved in the country. The insulin base at Chemz International is impressively productive, capable of producing over 3 tons of insulin-like raw materials and approximately 300 million units of preparations annually, contributing an annual output value exceeding RMB 10 billion.

In 2002, Chemz International established the Institute of Biology under the auspices of Zhuhai Chemz International Laboratories Co., Ltd. This institute is a thriving hub for scientific inquiry, employing nearly 100 researchers, over 30% of whom hold postgraduate degrees. It is equipped with nearly 100 pieces of large R&D equipment and has invested over 60 million yuan in fixed assets. The institute has earned accolades as the “Enterprise Technology Center in Guangdong Province,” “Engineering Technology R&D Center in Guangdong Province,” and a “Post-Doctoral Research Center.” In November 2014, the Guangdong Provincial Science & Technology Department approved the institute’s application to establish the Guangdong Engineering Technology Center of Diabetic Biological Medicine.

The institute primarily focuses on the research of diabetic biological medicine and diabetes-related biological products. It currently manages 15 biotech drug projects and has applied for 22 patents, 16 of which have been authorized, with several others in the application process. Its major products include rh-insulin – USLIN® (R, N, 30R, and 50R) and the human insulin analogue – insulin glargine USLEN®. Notably, Chemz International is the second manufacturer in the nation to receive approval for producing insulin glargine, marking a significant milestone in its commitment to advancing diabetic care and treatment.